APO Research
Talk to an analyst

APO RESEARCH · REPORT

Blood Cancer Chemotherapy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Blood Cancer Chemotherapy Drugs Market Outlook and Growth Opportunities 2026

23 December 2025204 pages

Choose your research edition.

Industry ResearchBlood Cancer Chemotherapy Drugs Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Blood Cancer Chemotherapy Drugs Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Blood Cancer Chemotherapy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Blood Cancer Chemotherapy Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Blood Cancer Chemotherapy Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Blood Cancer Chemotherapy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Blood Cancer Chemotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Blood Cancer Chemotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Blood Cancer Chemotherapy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Blood Cancer Chemotherapy Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Blood Cancer Chemotherapy Drugs market include CHIA TAI Tianqing Pharmaceutical, Hisunpharm, Takeda, Shenzhen Main Luck Pharmaceuticals, Sanofi, Johnson And Johnson, Novartis, Merck and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Blood Cancer Chemotherapy Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Blood Cancer Chemotherapy Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Blood Cancer Chemotherapy Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Blood Cancer Chemotherapy Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Blood Cancer Chemotherapy Drugs Segment by Company

CHIA TAI Tianqing Pharmaceutical

Hisunpharm

Takeda

Shenzhen Main Luck Pharmaceuticals

Sanofi

Johnson And Johnson

Novartis

Merck

Roche

Lunan Pharmaceutical Group

Eli Lilly

Gilead Sciences

Pfizer

Hainan Periwinkle Pharmaceutical

Amgen

AbbVie

AstraZeneca

Regeneron Pharmaceuticals

Celgene

BristolMyers Squibb

Blood Cancer Chemotherapy Drugs Segment by Type

Plant Based Anti-Tumor Drugs

Alkylating Agents

Antitumor Antibiotics

Anti Metabolic Drugs

Others

Blood Cancer Chemotherapy Drugs Segment by Application

Lymphoma

Multiple Myeloma

Leukemia

Other Blood Tumors

Blood Cancer Chemotherapy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Blood Cancer Chemotherapy Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Blood Cancer Chemotherapy Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Blood Cancer Chemotherapy Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Blood Cancer Chemotherapy Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Cancer Chemotherapy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Blood Cancer Chemotherapy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Cancer Chemotherapy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Blood Cancer Chemotherapy Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Blood Cancer Chemotherapy Drugs industry.

Chapter 3: Detailed analysis of Blood Cancer Chemotherapy Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Blood Cancer Chemotherapy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Blood Cancer Chemotherapy Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Blood Cancer Chemotherapy Drugs Industry Trends Table 2. Blood Cancer Chemotherapy Drugs Industry Drivers Table 3. Blood Cancer Chemotherapy Drugs Industry Opportunities and Challenges Table 4. Blood Cancer Chemotherapy Drugs Industry Restraints Table 5. Global Blood Cancer Chemotherapy Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Blood Cancer Chemotherapy Drugs Revenue Share by Company (2021-2026) Table 7. Global Blood Cancer Chemotherapy Drugs Sales Volume by Company (units) & (2021-2026) Table 8. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Blood Cancer Chemotherapy Drugs Average Price (USD/unit) of Company (2021-2026) Table 10. Global Blood Cancer Chemotherapy Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Blood Cancer Chemotherapy Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Blood Cancer Chemotherapy Drugs Company, Product Type & Application Table 13. Global Blood Cancer Chemotherapy Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Blood Cancer Chemotherapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Plant Based Anti-Tumor Drugs Table 18. Significant Companies of Alkylating Agents Table 19. Significant Companies of Antitumor Antibiotics Table 20. Significant Companies of Anti Metabolic Drugs Table 21. Significant Companies of Others Table 22. Global Blood Cancer Chemotherapy Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (units) Table 23. Global Blood Cancer Chemotherapy Drugs Sales Volume by Type (2021-2026) & (units) Table 24. Global Blood Cancer Chemotherapy Drugs Sales Volume by Type (2027-2032) & (units) Table 25. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Blood Cancer Chemotherapy Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Blood Cancer Chemotherapy Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Blood Cancer Chemotherapy Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Type (2021-2026) Table 31. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Lymphoma Table 33. Significant Companies of Multiple Myeloma Table 34. Significant Companies of Leukemia Table 35. Significant Companies of Other Blood Tumors Table 36. Global Blood Cancer Chemotherapy Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (units) Table 37. Global Blood Cancer Chemotherapy Drugs Sales Volume by Application (2021-2026) & (units) Table 38. Global Blood Cancer Chemotherapy Drugs Sales Volume by Application (2027-2032) & (units) Table 39. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Blood Cancer Chemotherapy Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Blood Cancer Chemotherapy Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Blood Cancer Chemotherapy Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Application (2021-2026) Table 45. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Application (2027-2032) Table 46. Global Blood Cancer Chemotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Table 47. Global Blood Cancer Chemotherapy Drugs Sales by Region (2021-2026) & (units) Table 48. Global Blood Cancer Chemotherapy Drugs Sales Market Share by Region (2021-2026) Table 49. Global Blood Cancer Chemotherapy Drugs Sales by Region (2027-2032) & (units) Table 50. Global Blood Cancer Chemotherapy Drugs Sales Market Share by Region (2027-2032) Table 51. Global Blood Cancer Chemotherapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Blood Cancer Chemotherapy Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Region (2021-2026) Table 54. Global Blood Cancer Chemotherapy Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Region (2027-2032) Table 56. Global Blood Cancer Chemotherapy Drugs Market Average Price (USD/unit) by Region (2021-2026) Table 57. Global Blood Cancer Chemotherapy Drugs Market Average Price (USD/unit) by Region (2027-2032) Table 58. Global Blood Cancer Chemotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032 (units) Table 59. Global Blood Cancer Chemotherapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Blood Cancer Chemotherapy Drugs Sales by Country (2021-2026) & (units) Table 61. Global Blood Cancer Chemotherapy Drugs Sales Market Share by Country (2021-2026) Table 62. Global Blood Cancer Chemotherapy Drugs Sales by Country (2027-2032) & (units) Table 63. Global Blood Cancer Chemotherapy Drugs Sales Market Share by Country (2027-2032) Table 64. Global Blood Cancer Chemotherapy Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Blood Cancer Chemotherapy Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Blood Cancer Chemotherapy Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Blood Cancer Chemotherapy Drugs Sales Value Market Share by Country (2027-2032) Table 68. CHIA TAI Tianqing Pharmaceutical Company Information Table 69. CHIA TAI Tianqing Pharmaceutical Business Overview Table 70. CHIA TAI Tianqing Pharmaceutical Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. CHIA TAI Tianqing Pharmaceutical Blood Cancer Chemotherapy Drugs Product Portfolio Table 72. CHIA TAI Tianqing Pharmaceutical Recent Development Table 73. Hisunpharm Company Information Table 74. Hisunpharm Business Overview Table 75. Hisunpharm Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Hisunpharm Blood Cancer Chemotherapy Drugs Product Portfolio Table 77. Hisunpharm Recent Development Table 78. Takeda Company Information Table 79. Takeda Business Overview Table 80. Takeda Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Takeda Blood Cancer Chemotherapy Drugs Product Portfolio Table 82. Takeda Recent Development Table 83. Shenzhen Main Luck Pharmaceuticals Company Information Table 84. Shenzhen Main Luck Pharmaceuticals Business Overview Table 85. Shenzhen Main Luck Pharmaceuticals Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. Shenzhen Main Luck Pharmaceuticals Blood Cancer Chemotherapy Drugs Product Portfolio Table 87. Shenzhen Main Luck Pharmaceuticals Recent Development Table 88. Sanofi Company Information Table 89. Sanofi Business Overview Table 90. Sanofi Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Sanofi Blood Cancer Chemotherapy Drugs Product Portfolio Table 92. Sanofi Recent Development Table 93. Johnson And Johnson Company Information Table 94. Johnson And Johnson Business Overview Table 95. Johnson And Johnson Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 96. Johnson And Johnson Blood Cancer Chemotherapy Drugs Product Portfolio Table 97. Johnson And Johnson Recent Development Table 98. Novartis Company Information Table 99. Novartis Business Overview Table 100. Novartis Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 101. Novartis Blood Cancer Chemotherapy Drugs Product Portfolio Table 102. Novartis Recent Development Table 103. Merck Company Information Table 104. Merck Business Overview Table 105. Merck Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 106. Merck Blood Cancer Chemotherapy Drugs Product Portfolio Table 107. Merck Recent Development Table 108. Roche Company Information Table 109. Roche Business Overview Table 110. Roche Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 111. Roche Blood Cancer Chemotherapy Drugs Product Portfolio Table 112. Roche Recent Development Table 113. Lunan Pharmaceutical Group Company Information Table 114. Lunan Pharmaceutical Group Business Overview Table 115. Lunan Pharmaceutical Group Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 116. Lunan Pharmaceutical Group Blood Cancer Chemotherapy Drugs Product Portfolio Table 117. Lunan Pharmaceutical Group Recent Development Table 118. Eli Lilly Company Information Table 119. Eli Lilly Business Overview Table 120. Eli Lilly Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 121. Eli Lilly Blood Cancer Chemotherapy Drugs Product Portfolio Table 122. Eli Lilly Recent Development Table 123. Gilead Sciences Company Information Table 124. Gilead Sciences Business Overview Table 125. Gilead Sciences Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 126. Gilead Sciences Blood Cancer Chemotherapy Drugs Product Portfolio Table 127. Gilead Sciences Recent Development Table 128. Pfizer Company Information Table 129. Pfizer Business Overview Table 130. Pfizer Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 131. Pfizer Blood Cancer Chemotherapy Drugs Product Portfolio Table 132. Pfizer Recent Development Table 133. Hainan Periwinkle Pharmaceutical Company Information Table 134. Hainan Periwinkle Pharmaceutical Business Overview Table 135. Hainan Periwinkle Pharmaceutical Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 136. Hainan Periwinkle Pharmaceutical Blood Cancer Chemotherapy Drugs Product Portfolio Table 137. Hainan Periwinkle Pharmaceutical Recent Development Table 138. Amgen Company Information Table 139. Amgen Business Overview Table 140. Amgen Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 141. Amgen Blood Cancer Chemotherapy Drugs Product Portfolio Table 142. Amgen Recent Development Table 143. AbbVie Company Information Table 144. AbbVie Business Overview Table 145. AbbVie Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 146. AbbVie Blood Cancer Chemotherapy Drugs Product Portfolio Table 147. AbbVie Recent Development Table 148. AstraZeneca Company Information Table 149. AstraZeneca Business Overview Table 150. AstraZeneca Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 151. AstraZeneca Blood Cancer Chemotherapy Drugs Product Portfolio Table 152. AstraZeneca Recent Development Table 153. Regeneron Pharmaceuticals Company Information Table 154. Regeneron Pharmaceuticals Business Overview Table 155. Regeneron Pharmaceuticals Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 156. Regeneron Pharmaceuticals Blood Cancer Chemotherapy Drugs Product Portfolio Table 157. Regeneron Pharmaceuticals Recent Development Table 158. Celgene Company Information Table 159. Celgene Business Overview Table 160. Celgene Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 161. Celgene Blood Cancer Chemotherapy Drugs Product Portfolio Table 162. Celgene Recent Development Table 163. BristolMyers Squibb Company Information Table 164. BristolMyers Squibb Business Overview Table 165. BristolMyers Squibb Blood Cancer Chemotherapy Drugs Sales (units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 166. BristolMyers Squibb Blood Cancer Chemotherapy Drugs Product Portfolio Table 167. BristolMyers Squibb Recent Development Table 168. Key Raw Materials Table 169. Raw Materials Key Suppliers Table 170. Blood Cancer Chemotherapy Drugs Distributors List Table 171. Blood Cancer Chemotherapy Drugs Customers List Table 172. Research Programs/Design for This Report Table 173. Authors List of This Report Table 174. Secondary Sources Table 175. Primary Sources List of Figures Figure 1. Blood Cancer Chemotherapy Drugs Product Image Figure 2. Global Blood Cancer Chemotherapy Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Blood Cancer Chemotherapy Drugs Sales (2021-2032) & (units) Figure 5. Global Blood Cancer Chemotherapy Drugs Sales Average Price (USD/unit) & (2021-2032) Figure 6. Global Blood Cancer Chemotherapy Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Plant Based Anti-Tumor Drugs Image Figure 10. Alkylating Agents Image Figure 11. Antitumor Antibiotics Image Figure 12. Anti Metabolic Drugs Image Figure 13. Others Image Figure 14. Global Blood Cancer Chemotherapy Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (units) Figure 15. Global Blood Cancer Chemotherapy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Blood Cancer Chemotherapy Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Blood Cancer Chemotherapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Type (2021-2032) Figure 20. Lymphoma Image Figure 21. Multiple Myeloma Image Figure 22. Leukemia Image Figure 23. Other Blood Tumors Image Figure 24. Global Blood Cancer Chemotherapy Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (units) Figure 25. Global Blood Cancer Chemotherapy Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Blood Cancer Chemotherapy Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Blood Cancer Chemotherapy Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Blood Cancer Chemotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032 (units) Figure 31. Global Blood Cancer Chemotherapy Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Blood Cancer Chemotherapy Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Blood Cancer Chemotherapy Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Blood Cancer Chemotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Blood Cancer Chemotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Blood Cancer Chemotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Blood Cancer Chemotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Blood Cancer Chemotherapy Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Blood Cancer Chemotherapy Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Blood Cancer Chemotherapy Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Blood Cancer Chemotherapy Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Plant Based Anti-Tumor Drugs
  • Alkylating Agents
  • Antitumor Antibiotics
  • Anti Metabolic Drugs
  • Others
Applications
  • Lymphoma
  • Multiple Myeloma
  • Leukemia
  • Other Blood Tumors
Companies covered
  • CHIA TAI Tianqing Pharmaceutical
  • Hisunpharm
  • Takeda
  • Shenzhen Main Luck Pharmaceuticals
  • Sanofi
  • Johnson And Johnson
  • Novartis
  • Merck
  • Roche
  • Lunan Pharmaceutical Group
  • Eli Lilly
  • Gilead Sciences
  • Pfizer
  • Hainan Periwinkle Pharmaceutical
  • Amgen
  • AbbVie
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Celgene
  • BristolMyers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Blood Cancer Chemotherapy Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Blood Cancer Chemotherapy Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Blood Cancer Chemotherapy Drugs Market Dynamics
  1. 2.1 Blood Cancer Chemotherapy Drugs Industry Trends
  2. 2.2 Blood Cancer Chemotherapy Drugs Industry Drivers
  3. 2.3 Blood Cancer Chemotherapy Drugs Industry Opportunities and Challenges
  4. 2.4 Blood Cancer Chemotherapy Drugs Industry Restraints
3 Blood Cancer Chemotherapy Drugs Market by Company
  1. 3.1 Global Blood Cancer Chemotherapy Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Blood Cancer Chemotherapy Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Blood Cancer Chemotherapy Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Blood Cancer Chemotherapy Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Blood Cancer Chemotherapy Drugs Company Ranking (2024-2026)
  6. 3.6 Global Blood Cancer Chemotherapy Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Blood Cancer Chemotherapy Drugs Company Product Type and Application
  8. 3.8 Global Blood Cancer Chemotherapy Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Blood Cancer Chemotherapy Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Blood Cancer Chemotherapy Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Blood Cancer Chemotherapy Drugs Market by Type
  1. 4.1 Blood Cancer Chemotherapy Drugs Type Introduction
  2. 4.1.1 Plant Based Anti-Tumor Drugs
  3. 4.1.2 Alkylating Agents
  4. 4.1.3 Antitumor Antibiotics
  5. 4.1.4 Anti Metabolic Drugs
  6. 4.1.5 Others
  7. 4.2 Global Blood Cancer Chemotherapy Drugs Sales Volume by Type
  8. 4.2.1 Global Blood Cancer Chemotherapy Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Blood Cancer Chemotherapy Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Blood Cancer Chemotherapy Drugs Sales Value by Type
  12. 4.3.1 Global Blood Cancer Chemotherapy Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Blood Cancer Chemotherapy Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Blood Cancer Chemotherapy Drugs Sales Value Share by Type (2021-2032)
5 Blood Cancer Chemotherapy Drugs Market by Application
  1. 5.1 Blood Cancer Chemotherapy Drugs Application Introduction
  2. 5.1.1 Lymphoma
  3. 5.1.2 Multiple Myeloma
  4. 5.1.3 Leukemia
  5. 5.1.4 Other Blood Tumors
  6. 5.2 Global Blood Cancer Chemotherapy Drugs Sales Volume by Application
  7. 5.2.1 Global Blood Cancer Chemotherapy Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Blood Cancer Chemotherapy Drugs Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Blood Cancer Chemotherapy Drugs Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Blood Cancer Chemotherapy Drugs Sales Value by Application
  11. 5.3.1 Global Blood Cancer Chemotherapy Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Blood Cancer Chemotherapy Drugs Sales Value by Application (2021-2032)
  13. 5.3.3 Global Blood Cancer Chemotherapy Drugs Sales Value Share by Application (2021-2032)
6 Blood Cancer Chemotherapy Drugs Regional Sales and Value Analysis
  1. 6.1 Global Blood Cancer Chemotherapy Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Blood Cancer Chemotherapy Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Blood Cancer Chemotherapy Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Blood Cancer Chemotherapy Drugs Sales by Region (2027-2032)
  5. 6.3 Global Blood Cancer Chemotherapy Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Blood Cancer Chemotherapy Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Blood Cancer Chemotherapy Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Blood Cancer Chemotherapy Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Blood Cancer Chemotherapy Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Blood Cancer Chemotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Blood Cancer Chemotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Blood Cancer Chemotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Blood Cancer Chemotherapy Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Blood Cancer Chemotherapy Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Blood Cancer Chemotherapy Drugs Sales Value Share by Country, 2025 VS 2032
7 Blood Cancer Chemotherapy Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Blood Cancer Chemotherapy Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Blood Cancer Chemotherapy Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Blood Cancer Chemotherapy Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Blood Cancer Chemotherapy Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Blood Cancer Chemotherapy Drugs Sales by Country (2027-2032)
  6. 7.4 Global Blood Cancer Chemotherapy Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Blood Cancer Chemotherapy Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Blood Cancer Chemotherapy Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Blood Cancer Chemotherapy Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Blood Cancer Chemotherapy Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Blood Cancer Chemotherapy Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CHIA TAI Tianqing Pharmaceutical
  2. 8.1.1 CHIA TAI Tianqing Pharmaceutical Company Information
  3. 8.1.2 CHIA TAI Tianqing Pharmaceutical Business Overview
  4. 8.1.3 CHIA TAI Tianqing Pharmaceutical Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CHIA TAI Tianqing Pharmaceutical Blood Cancer Chemotherapy Drugs Product Portfolio
  6. 8.1.5 CHIA TAI Tianqing Pharmaceutical Recent Developments
  7. 8.2 Hisunpharm
  8. 8.2.1 Hisunpharm Company Information
  9. 8.2.2 Hisunpharm Business Overview
  10. 8.2.3 Hisunpharm Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hisunpharm Blood Cancer Chemotherapy Drugs Product Portfolio
  12. 8.2.5 Hisunpharm Recent Developments
  13. 8.3 Takeda
  14. 8.3.1 Takeda Company Information
  15. 8.3.2 Takeda Business Overview
  16. 8.3.3 Takeda Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Takeda Blood Cancer Chemotherapy Drugs Product Portfolio
  18. 8.3.5 Takeda Recent Developments
  19. 8.4 Shenzhen Main Luck Pharmaceuticals
  20. 8.4.1 Shenzhen Main Luck Pharmaceuticals Company Information
  21. 8.4.2 Shenzhen Main Luck Pharmaceuticals Business Overview
  22. 8.4.3 Shenzhen Main Luck Pharmaceuticals Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shenzhen Main Luck Pharmaceuticals Blood Cancer Chemotherapy Drugs Product Portfolio
  24. 8.4.5 Shenzhen Main Luck Pharmaceuticals Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi Blood Cancer Chemotherapy Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Johnson And Johnson
  32. 8.6.1 Johnson And Johnson Company Information
  33. 8.6.2 Johnson And Johnson Business Overview
  34. 8.6.3 Johnson And Johnson Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Johnson And Johnson Blood Cancer Chemotherapy Drugs Product Portfolio
  36. 8.6.5 Johnson And Johnson Recent Developments
  37. 8.7 Novartis
  38. 8.7.1 Novartis Company Information
  39. 8.7.2 Novartis Business Overview
  40. 8.7.3 Novartis Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Novartis Blood Cancer Chemotherapy Drugs Product Portfolio
  42. 8.7.5 Novartis Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merck Blood Cancer Chemotherapy Drugs Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Roche Blood Cancer Chemotherapy Drugs Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Lunan Pharmaceutical Group
  56. 8.10.1 Lunan Pharmaceutical Group Company Information
  57. 8.10.2 Lunan Pharmaceutical Group Business Overview
  58. 8.10.3 Lunan Pharmaceutical Group Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lunan Pharmaceutical Group Blood Cancer Chemotherapy Drugs Product Portfolio
  60. 8.10.5 Lunan Pharmaceutical Group Recent Developments
  61. 8.11 Eli Lilly
  62. 8.11.1 Eli Lilly Company Information
  63. 8.11.2 Eli Lilly Business Overview
  64. 8.11.3 Eli Lilly Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Eli Lilly Blood Cancer Chemotherapy Drugs Product Portfolio
  66. 8.11.5 Eli Lilly Recent Developments
  67. 8.12 Gilead Sciences
  68. 8.12.1 Gilead Sciences Company Information
  69. 8.12.2 Gilead Sciences Business Overview
  70. 8.12.3 Gilead Sciences Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Gilead Sciences Blood Cancer Chemotherapy Drugs Product Portfolio
  72. 8.12.5 Gilead Sciences Recent Developments
  73. 8.13 Pfizer
  74. 8.13.1 Pfizer Company Information
  75. 8.13.2 Pfizer Business Overview
  76. 8.13.3 Pfizer Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Pfizer Blood Cancer Chemotherapy Drugs Product Portfolio
  78. 8.13.5 Pfizer Recent Developments
  79. 8.14 Hainan Periwinkle Pharmaceutical
  80. 8.14.1 Hainan Periwinkle Pharmaceutical Company Information
  81. 8.14.2 Hainan Periwinkle Pharmaceutical Business Overview
  82. 8.14.3 Hainan Periwinkle Pharmaceutical Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Hainan Periwinkle Pharmaceutical Blood Cancer Chemotherapy Drugs Product Portfolio
  84. 8.14.5 Hainan Periwinkle Pharmaceutical Recent Developments
  85. 8.15 Amgen
  86. 8.15.1 Amgen Company Information
  87. 8.15.2 Amgen Business Overview
  88. 8.15.3 Amgen Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Amgen Blood Cancer Chemotherapy Drugs Product Portfolio
  90. 8.15.5 Amgen Recent Developments
  91. 8.16 AbbVie
  92. 8.16.1 AbbVie Company Information
  93. 8.16.2 AbbVie Business Overview
  94. 8.16.3 AbbVie Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AbbVie Blood Cancer Chemotherapy Drugs Product Portfolio
  96. 8.16.5 AbbVie Recent Developments
  97. 8.17 AstraZeneca
  98. 8.17.1 AstraZeneca Company Information
  99. 8.17.2 AstraZeneca Business Overview
  100. 8.17.3 AstraZeneca Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 AstraZeneca Blood Cancer Chemotherapy Drugs Product Portfolio
  102. 8.17.5 AstraZeneca Recent Developments
  103. 8.18 Regeneron Pharmaceuticals
  104. 8.18.1 Regeneron Pharmaceuticals Company Information
  105. 8.18.2 Regeneron Pharmaceuticals Business Overview
  106. 8.18.3 Regeneron Pharmaceuticals Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Regeneron Pharmaceuticals Blood Cancer Chemotherapy Drugs Product Portfolio
  108. 8.18.5 Regeneron Pharmaceuticals Recent Developments
  109. 8.19 Celgene
  110. 8.19.1 Celgene Company Information
  111. 8.19.2 Celgene Business Overview
  112. 8.19.3 Celgene Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Celgene Blood Cancer Chemotherapy Drugs Product Portfolio
  114. 8.19.5 Celgene Recent Developments
  115. 8.20 BristolMyers Squibb
  116. 8.20.1 BristolMyers Squibb Company Information
  117. 8.20.2 BristolMyers Squibb Business Overview
  118. 8.20.3 BristolMyers Squibb Blood Cancer Chemotherapy Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 BristolMyers Squibb Blood Cancer Chemotherapy Drugs Product Portfolio
  120. 8.20.5 BristolMyers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Blood Cancer Chemotherapy Drugs Value Chain Analysis
  2. 9.1.1 Blood Cancer Chemotherapy Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Blood Cancer Chemotherapy Drugs Sales Mode & Process
  6. 9.2 Blood Cancer Chemotherapy Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Blood Cancer Chemotherapy Drugs Distributors
  9. 9.2.3 Blood Cancer Chemotherapy Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst